GSK tops quarterly forecasts, helped by COVID-19 treatment and Shingrix
(Reuters) -British pharmaceuticals giant GSK beat analyst expectations for its first-quarter results on Wednesday and stood by its 2022 forecasts, after buoyant sales of its COVID-19 treatment which has now been withdrawn from the U.S. market.